title: The optimal filler: immediate and long-term results with emulsified silicone (1,000 centistokes) with cross-linked hyaluronic acid.
abstract: BACKGROUND
  Silicone is one of the oldest and longest lasting of the dermal fillers. Microdroplet silicone injections have proven to be safe and effective. This paper describes how to obtain microdroplet silicone (1,000 centistokes) in a consistent manner, including a discussion of its efficacy and safety.
  
  
  METHODS
  A simple, permanent method of tissue augmentation is described. U.S. Food and Drug Administration- approved liquid silicone (Silikon®) is emulsified with cross-linked hyaluronic acid through a Luer-Lok to Luer-Lok connector between two 3-cc syringes. This stable emulsion is injected through a 27G needle or through a 25G or 27G microcannula into the middermis, subcutaneous tissue, or periosteum.
  
  
  RESULTS
  The results of 95 cases are described. The emulsion is most beneficial for distensible acne valleys, nasolabial folds, glabellar frown lines, augmentation of the vermilion border of the lips, and projection of the nose, cheekbones, and chin. Exterior nasal deviations and soft tissue defects are also improved. Complications are minimal and include temporary bruising, erythema, and mild edema. Any temporary small nodules are easily leveled with massage. Occasionally, it takes a repeat session at 1 month to completely elevate depressions. The resulting elevations remain stable during the 2-year follow-up period. No silicone granulomas have developed.
  
  
  CONCLUSIONS
  This methodology has replaced many indications for temporary, semipermanent, or permanent fillers.
authors.affiliation: Department of Dermatology, University of Miami, FL, USA.
authors.forename: James
authors.initials: J
authors.lastname: Fulton
authors.forename: Caroline
authors.initials: C
authors.lastname: Caperton
mesh_terms: D000328:Adult; D003357:Cosmetic Techniques; D003432:Cross-Linking Reagents / Q000737:chemistry; D004129:Dimethylpolysiloxanes / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
chemical_list: D003432:Cross-Linking Reagents; D004129:Dimethylpolysiloxanes; C013830:baysilon; D006820:Hyaluronic Acid